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Abstract
Objective: To analyze the neonatal screening program for hemoglobinopathies in São 
Carlos, Southeast Brazil, by investigating a series of cases in which the screening test was 
abnormal. More specifically, it was aimed to know the information regarding the neonatal 
screening received by mothers at the hospital and at primary health care, in addition to 
information related to genetic counseling.
Methods: A descriptive study that enrolled 119 mothers, accounting for 73% of all chil-
dren born between 2010 and 2011 with abnormal results of neonatal screening for he-
moglobinopathies. The mothers completed a questionnaire that assessed the information 
received at hospital and primary health care, and issues related to genetic counseling. 
Descriptive statistics was performed.
Results: Of the 119 participating mothers, 69 (58%) had children with sickle cell trait, 
22 (18.5%) with hemoglobin C trait, 18 (15.1%) with alpha thalassemia trait and, in 10 
cases (8.4%), the result was inconclusive. At the hospital, 118 mothers (99.2%) received 
information about where to go to collect the test and 115 (96.6%) were informed about 
the correct time to collect the test. Only 4 mothers (3.4%) were informed about which di-
seases are investigated and the risks of not performing the screening. Seventeen mothers 
(14.3%) recognized the difference between trait and disease, and 42 (35.3%) considered 
that a positive screening test could have implications for future pregnancies. In 70 cases 
(58.8%), the child’s physician was not informed about the screening test results. 
*Corresponding author.
E-mails: debora.gusmao@gmail.com; dgmelo@ufscar.br (D.G. Melo).
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Conclusions: The neonatal screening program needs further improvement. In both sce-
narios investigated, health professionals demonstrated a lack of training in providing 
information to mothers and families. 
© 2014 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
Triagem neonatal de hemoglobinopatias no município de São Carlos, São Paulo, Brasil: 
análise de uma série de casos
Resumo
Objetivo: Realizar uma análise do programa de triagem neonatal de hemoglobinopatias 
no município de São Carlos, São Paulo, Brasil, por meio da investigação de série de casos 
cujo resultado do teste de rastreio foi alterado. Objetivou-se conhecer as informações a 
respeito da triagem neonatal recebidas pelas mães na maternidade e na atenção primária 
à saúde, além das informações relacionadas à orientação genética.
Métodos: Estudo descritivo, no qual participaram 119 mães cujos filhos apresentaram 
teste de triagem de hemoglobinopatia alterado, correspondendo a 73% das crianças na-
scidas entre 2010 e 2011 com resultado de triagem neonatal para hemoglobinopatia 
anormal. As mães responderam a um questionário que avaliou informações recebidas na 
maternidade e na atenção primária à saúde, além aspectos relacionados à orientação 
genética. Foi realizada estatística descritiva dos dados.
Resultados: Das 119 mães participantes, 69 (58%) possuíam filhos com traço falciforme, 
22 (18,5%) traço C, 18 (15,1%) traço alfa talassêmico e, em 10 (8,4%) casos, o resultado 
foi inconclusivo. Na maternidade, 118 mães (99,2%) receberam informação sobre onde ir 
e 115 (96,6%) foram orientadas sobre o momento correto para coleta do teste. Somente 
4 mães (3,4%) foram informadas sobre quais doenças seriam investigadas e os riscos de 
não realizar o rastreio. Das 119 mães participantes, 17 (14,3%) reconheceram a dife-
rença entre traço e doença e 42 (35,3%) consideraram que um teste alterado poderia ter 
implicações para futuras gestações. Em 70 casos (58,8%), o médico da criança não foi 
informado sobre o resultado da triagem.
Conclusões: O programa de triagem neonatal necessita de aperfeiçoamento. Nos dois 
cenários investigados, os profissionais de saúde carecem de treinamento para orientar 
mães e famílias.
© 2014 Sociedade de Pediatria de São Paulo. Publicado por Elsevier Editora Ltda. Todos os 
direitos reservados.
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Introduction
Neonatal screening allows the early identification of sever-
al congenital diseases that have no symptoms at birth, in 
order to intervene in its natural course, thus attenuating 
the clinical consequences. The criteria used for the inclu-
sion of a disease in a neonatal screening program in gener-
al follow those proposed by James Wilson and Gunnar 
Jungner in 1968: the condition being screened must be an 
important health problem; the natural history of the dis-
ease needs to be well known; there must be an identifiable 
early stage; early treatment should bring greater benefits 
than at later stages; an adequate test should be developed 
for the early stage; the test should be acceptable to the 
population; retesting intervals should be determined; 
health care services need to be adequate for the extra clin-
ical work resulting from screening; risks, both physical and 
psychological, should be fewer than the benefits.1
In Brazil, in 2001, the Ministry of Health established the 
National Neonatal Screening Program (PNTN) with the 
objective of expanding the existing screening program at 
the time (restricted to phenylketonuria and congenital 
hypothyroidism), including the identification of other con-
genital diseases, such as hemoglobinopathies and cystic 
fibrosis.2 Moreover, the PNTN established a comprehensive 
approach of the subject, involving early detection, 
increased population coverage, active search for patients, 
diagnostic confirmation, follow-up and treatment, and the 
creation of an information system to register patients.3
PNTN was designed as a five-step system, usually orga-
nized and conducted by the public health system, which 
has the necessary conditions and authority to carry out uni-
versal screening, in which the pediatrician plays an import-
ant role.4 The first step comprises the screening test itself 
and it aims at the universal coverage of screening, i.e., 
that all newborns be tested. Obstetricians and pediatri-
cians are essential at this stage. Parents need to know 
about the existence of neonatal screening and be coun-
seled beforehand about which diseases will be screened 
and benefits of early detection, the risks for the newborn 
who is not submitted to the test, the appropriate age for 
its performance, the need for subsequent confirmatory 
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tests for those who test positive, the possibility of false-pos-
itives, the process of monitoring and receiving the results. 
The second step comprises the active search, with the 
monitoring of results and locating the newborn and the 
family, especially if the results are altered. The third step 
comprises performing diagnostic tests, which vary accord-
ing to the disease and often require specialized laborato-
ries. The fourth step concerns the treatment, when neces-
sary. Finally, the fifth step is the periodic evaluation of all 
previous steps and different system components: validation 
of tests used, assessing the efficacy of active search and 
intervention, evaluating the benefits to the patient, the 
family and society.4
The implementation of the PNTN in Brazil was originally 
designed to occur in phases, according to the level of orga-
nization and coverage of each state of the Federation: in 
phase I, the diseases screened for are phenylketonuria and 
congenital hypothyroidism; in phase II, screening for hemo-
globinopathies is added to the panel; in phase III, screening 
for cystic fibrosis is added.4 In late 2012, the Ministry of 
Health authorized the increase of the PNTN into a phase IV, 
which included the screening of adrenal hyperplasia and 
biotinidase deficiency.5 Currently, 18 units of the federa-
tion (including São Paulo) and the Federal District are in 
phase IV of the PNTN, and nine states are in Phase III.6
Hemoglobinopathies are a heterogeneous group of more 
than 100 inherited diseases, mostly autosomal recessive, 
with more than 1,000 different mutant alleles character-
ized at the molecular level, responsible for changes in the 
structure or synthesis of the hemoglobin molecule, repre-
sented mainly by hemoglobin S and C (HbS and HbC), as 
well as alpha and beta thalassemia.7 In Brazil, HbS is pres-
ent mainly in the African descendants, and sickle-cell ane-
mia (homozygous form of HbS) is the most common genetic 
disease in the country, with an estimated incidence of 
1-3:1,000 live births.8 It is estimated that there are two 
million individuals with sickle cell trait (heterozygous HbS), 
and eight thousand individuals with sickle cell disease, with 
the Southeast and Northeast regions being the most affect-
ed.9 Data from the Ministry of Health, in 2012, showed that 
the incidence of sickle cell anemia was 1:650 in Bahia, 
1:1,300 in Rio de Janeiro, and 1:1,400 in Minas Gerais. 
These are the three most affected states of the federation, 
with a frequency of sickle cell trait of 1:17, 1:20 and 1:30, 
respectively.10 Neonatal screening is the starting point to 
implement simple secondary prevention strategies for sick-
le cell disease, which include parental education, pneumo-
coccal immunization and prophylaxis with penicillin.11,12
In São Carlos, neonatal screening for hemoglobinopathies 
started in 1999, so when the PNTN was implemented, the 
city was already in phase II. Located in the geographic cen-
ter of the state of São Paulo, São Carlos has approximately 
220,000 inhabitants, with approximately 2,700 births/
year,13 and in 2010 its human development index was 0.805, 
being considered the 28th most developed municipality in 
the country.14 A previous study carried out in the city 
showed that the PNTN coverage between the years 2007 
and 2010 was, on average, 93.6%, higher than the national 
and state levels.15 In general, there is significant heteroge-
neity in the distribution of PNTN coverage in Brazil, reflect-
ing the economic, social, political, cultural and health care 
diversity.16 In this context, in São Carlos, the current con-
cern should be primarily to evaluate whether subsequent 
PNTN steps, in addition to the screening test completion, 
are being adequately performed. 
In this context, the present study aimed to carry out an 
analysis of a neonatal screening program for hemoglobinop-
athies in São Carlos, state of São Paulo, by assessing a series 
of cases whose screening test results was altered. More spe-
cifically, it was aimed to know the information about neona-
tal screening received by mothers in maternity hospitals and 
primary health care services, in addition to information 
related to genetic counseling that mothers had. Finally, it 
aimed to contribute to the creation of a line of comprehen-
sive care for patients with hemoglobinopathies.
Method
This is a descriptive study, previously approved by the 
Ethics Committee on Human Research of UFSCar (number: 
121,661) and carried out in the year 2013. Mothers of chil-
dren born in 2010 and 2011 that had an altered result at the 
screening test for hemoglobinopathies were invited to par-
ticipate in the study. Participation was conditional on sign-
ing the Free and Informed Consent form.
Initially, data on the PNTN were obtained from 
Epidemiological Surveillance, identifying 81 children born 
in 2010 and 82 in 2011 with altered results at the screening 
test for hemoglobinopathies, which totaled 163 eligible 
mothers for the study.
There was no refusal to participate in the study among 
the located mothers; however, in 44 cases (27%), the fami-
ly could not be located and invited to participate in the 
study. Thus, 119 mothers were located and invited to par-
ticipate in the study, representing 73% of the total 163 pos-
sible participants.
The 119 mothers who agreed to participate were invited 
to attend the Primary Health Care Units to which the fam-
ilies were referred and interviewed using a standardized 
questionnaire developed specifically for this research, used 
as a data collection tool. The questionnaire was applied by 
two medical undergraduate students, under the supervision 
of a physician specialized in hematology. The participants’ 
questions were clarified as the questionnaire was filled 
out. 
The questionnaire consisted of 24 questions, divided into 
four parts: (a) the first 10 questions were about the skin 
color of the father, mother and child, and also about the 
family’s socioeconomic status; (b) four questions on infor-
mation received by the mother in the maternity hospital 
regarding neonatal screening; (c) three questions on infor-
mation received by the mother in Primary Health Care ser-
vices during the screening test collection, and (d) seven 
questions related to family genetic counseling provided to 
the mother due to the presence of an altered screening 
test result in the child. Information about skin color was 
reported by mothers; the classification of the Brazilian 
Institute of Geography and Statistics (IBGE) was used to 
categorize this variable as: white, black, yellow, brown or 
Brazilian native. Descriptive statistics of the collected data 
was performed.
22 de Azevedo Silva C et al
Results
A total of 119 mothers whose children had an altered 
hemoglobin screening test participated in the study. None 
of the children participating in the study was sick, all 
were heterozygous, i.e., they had an abnormal hemoglo-
bin trait. Sixty-nine participants (58%) had children with 
sickle-cell trait (HbS); 22 (18.5%) with trace C (HbC); 18 
(15.1%) with alpha-thalassemia trait, identified by the 
presence of Hb Bart’s; and in 10 cases (8.4%) the result of 
the screening was inconclusive, i.e., it was not possible to 
define the hemoglobinopathy pattern, suggesting a possi-
ble rare hemoglobin, specifically non-identified by labora-
tory methods used in the testing (Electrophoresis by 
Isoelectric Focusing and High Resolution Liquid chroma-
tography).
Table 1 shows the skin color distribution and socioeco-
nomic profile of this population.
The data shown in Figure 1 reflect the information that 
mothers received on neonatal screening in the maternity 
hospital. In only one case (0.8%) the mother reported not 
having received any information about neonatal screening 
in the maternity hospital; on the other 111 cases (93.3%) 
the nurse was the health professional involved in the trans-
mission of this information, with physicians being responsi-
ble for only seven cases (5.9%).
The data shown in Figure 2 translate the information 
received by mothers in the Primary Health Care (PHC) unit 
at the time of the neonatal screening test collection. In all 
119 cases, the screening test was collected in the first 
week of life of the newborn. The waiting time for test 
results averaged 35±42 days, with a median of 30 days, 
minimum of seven days and a maximum of 110 days. 
The data shown in Figure 3 refer to information related 
to genetic counseling that the mothers received, such as 
information about the hereditary characteristic of hemo-
globinopathies, recognizing the difference between trait 
and disease and the possible implications of the altered 
test for future pregnancies. In eight cases (6.7%), the fam-
ilies had not returned to the Health Care Unit and were 
advised in relation to the presence of hemoglobinopathy in 
the family through this research. As for the other 110 cases 
(92.5%) the information was provided by the nurse, and in 
one case (0.8%) the information was provided by a doctor. 
The frequency of relatives tested was of 72 mothers 
(60.5%), 17 fathers (14.3%) and 31 siblings (26.1%); the 
results of tests performed in these families were not avail-
able for consultation.
Discussion
Neonatal screening is currently the best known, and more 
often used worldwide, public health and preventive pediat-
ric practice related to genetics. In São Carlos, the PNTN 
coverage between the years 2007 and 2010 was, on aver-
age, of 93.6%,15 which is greater than the mean national 
coverage in 2011, which was 83%.17 In a study of 30 cities in 
the state of São Paulo, 57% of municipalities had coverage 
>90%, 27% of the analyzed cities had coverage between 90 
and 80%, 7% between 80 and 70%, and 10% had coverage 
<70%.18 Therefore, the municipality of São Carlos has high 
coverage in relation to national rates and is in line with 
other cities in the state of São Paulo. Although the cover-
age is an essential parameter, one cannot evaluate a neo-
natal screening program without analyzing the course of 
care of children with abnormal results and the guidance 
offered to their families. When proposing the screening, 
the health system should have the necessary infrastructure 
to confirm laboratory diagnosis for screened newborns, 
Table 1 Ethnicity and socioeconomic profile of the families that participated in the study.
Father
n (%)
Mother
n (%)
Child
n (%)
Ethnicity
White 37 (31.1%) 39 (32.8%) 59 (49.6%)
Mixed-race 62 (52.1%) 54 (45.4%) 50 (42.0%)
Black 20 (16.8%) 26 (21.8%) 10 (8.4%)
Level of schooling
Elementary School 10 (8.4%) —
Elementary I (1st to 5th Grades) 19 (15.%) 12 (10.1%)
Elementary II (6th to 9th Grades) 32 (26.9%) 36 (30.3%)
High School 54 (45.4%) 69 (57.9%)
College/University 4 (3.4%) 2 (1.7%)
Parents’ marital status
Living together 106 (89.1%)
Not living together 13 (10.9%)
Family income per capita
Up to 1/2 minimum wage 45 (37.8%)
Between 1/2 and 1 minimum wage 62 (52.1%)
Between 1 and 2 minimum wages 12 (10.1%)
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Figure 1 Information received by mothers in the maternity hospital on neonatal screening.
Figure 2 Information received by mothers in Primary Health Care related to the neonatal screening test.
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provide treatment and appropriate counseling; without it, 
the benefits achieved by early identification are not per-
petuated.16
Between 2010 and 2011, 163 children with altered results 
in the neonatal screening for hemoglobinopathies were 
identified in São Carlos, corresponding to a prevalence of 
2.8%, with a prevalence of sickle cell trait, which alone 
showed a prevalence of 1.2%.
Hemoglobin S and C originated in Africa, propagating 
widely in the Americas through slave trade.19,20 Thus, the 
distribution of these hemoglobinopathies is quite heteroge-
neous in the country, depending on the ethnic characteris-
tics of the population. A study carried out by the Ministry 
of Health showed that the prevalence of sickle cell trait in 
the state of Bahia is 5.3%, in Pernambuco and Rio de Janeiro 
it is 4.0%, in Minas Gerais it is 3.0%, in São Paulo 2.6 %, and 
in Rio Grande do Sul, 2.0%.21 The low prevalence of hemo-
globin S and C in São Carlos possibly reflects the ethnic 
composition of the population, strongly marked by the 
presence of (mainly Italian) European migration,22 so that 
73% of the citizens self-reported as being Caucasian in the 
2010 Census.13
In the present study, we were able to locate and inter-
view 73% of the 163 identified mothers. Address errors were 
the main obstacle to locating households, reflecting a cer-
tain lack of capacity by the Basic Health Unit (BHU) to orga-
nize and maintain updated records of their clients. In San 
Carlos, the collection of biological material (blood) for 
screening is performed in the BHUs. This material is stored 
in filter paper and sent to Epidemiological Surveillance, 
which sends the material to the Associação dos Pais e Amigos 
dos Excepcionais de São Paulo (APAE-SP), where laboratory 
tests are performed. The State of São Paulo has four Referral 
Services for Neonatal Screening (SRTN), accredited with the 
PNTN and treating patients from the Brazilian Public Health 
Care Network (SUS), with APAE-SP being the main Neonatal 
Referral Screening Service, responsible for 64% of all tests 
performed in the public health care network.23 There is no 
direct communication routine between APAE-SP and the 
BHUs of the municipality, with this dialogue being interme-
diated by Epidemiological Surveillance.
A study carried out in Natal, Rio Grande do Norte, based 
on 1,940 umbilical cord blood samples from newborns of 
three maternity hospitals in the city, identified 37 cases of 
abnormal hemoglobin (prevalence of 1.9%), of which 29 
(1.5%) had sickle cell trait (HbS), six (0.31%) had C trace 
(HbC), one (0.05%) had sickle cell anemia (HbSS) and one 
(0.05%) had Hb Bart’s (suggesting alpha thalassemia trait). In 
this study, correspondence was sent to the newborns’ moth-
ers, inviting them to attend a specialized, outpatient clinic 
and providing them genetic counseling. Of the 37 children 
identified, only 10 (27.2%) returned for diagnostic confirma-
tion and family investigation. It was presumed that the 
return consultation was hindered by difficulties locating the 
address, lack of sufficient knowledge about the importance 
of the diagnosis of these genetic alterations, and the reduced 
purchasing power of most families.24
A study carried out in the city of Marília, São Paulo, 
between the years 2004 and 2006, evaluated the perfor-
mance of the heel prick test, the medical follow-up and 
prophylactic measures offered, including treatment of chil-
dren diagnosed with sickle cell disease. During this period, 
Figure 3 Information related to genetic information that mothers had.
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the coverage of the municipality for neonatal screening 
was of 96.7%, and, as in our study, data collection ran into 
difficulties related to lack of information on patient fol-
low-up by the HBU. In only one of six cases of sickle cell 
disease identified in the sample, the patient was correctly 
referred to a specialized center. In another case, before 
the child’s diagnosis was known, they were hospitalized 
with complications due to lack of communication between 
the laboratory that had performed the screening test and 
the BHU that had not yet received the result and warned 
the family.25 These results are similar to ours, as we also 
observed a lack of communication between different sec-
tors of the health care system and identified the need to 
establish protocols and continuing education of health pro-
fessionals in relation to PNTN. 
We observe that the maternity hospital has partially ful-
filled its role to advise on neonatal screening. The BHU 
performs the collection as recommended, but it does not 
complete all subsequent stages of PNTN efficiently, even 
having difficulty locating children whose screening test was 
altered, which explains the fact that, in eight cases (6.7%), 
the parents were informed of the presence of hemoglob-
inopathy in the family through this study. Longitudinal care 
is not established, as the pediatrician or family doctor does 
not always know the result of the child’s neonatal screen-
ing. Information related to genetic counseling is transmit-
ted in a contingent, non-systematic way, and probably 
because of that many mothers cannot discern between the 
condition of heterozygosity (“trait”) and homozygosity (dis-
ease), and do not recognize the possible implications of the 
presence of hemoglobinopathy in the family.
The misperception between disease and trait is one of 
the severe problems found in neonatal screening programs 
for hemoglobinopathies. Ramalho et al reported on the dis-
tress of parents of newborns who received the letter from 
the Neonatal Screening Service stating that the child had a 
“trait”, as they understood that the child had an intellec-
tual disability or other relevant clinical finding.24 It is very 
important that patients, health professionals and the com-
munity in general understand that the condition of “trait” 
(either sickle cell, C or thalassemia trait) is not a disease 
and it is not an attenuated or incubated form of anemia, 
which can transform into the disease under certain circum-
stances. The sickling of red blood cells in individuals with 
sickle cell trait is rare, occurring only in situations of very 
intense hypoxia and/or acidosis.3,8
A study carried out in the city of Dourados, state of Mato 
Grosso do Sul, assessed the efficiency of PNTN for hemoglo-
binopathies in the years 2001-2005, by analyzing the pro-
gram’s coverage, prevalence of alterations, follow-up of 
altered cases and the understanding of the families regard-
ing explanations about the disease and genetic counseling. 
This study found 242 children with altered test results for 
hemoglobinopathies and the mothers of 32 of them were 
selected to answer a questionnaire. The results showed 
81.4% of neonatal screening coverage in this municipality. 
Of the 32 assessed families, 20 children (62.5%) were 
retested and 29 (90.6%) were referred to specialized med-
ical services. These same 29 (90.6%) received requests for 
blood tests in family members, and in 25 cases (86.2%) the 
blood collection was performed in fathers and mothers, 
whereas in four cases (13.8%) only in the mother. The par-
ents’ understanding about the genetic counseling informa-
tion was divided into satisfactory (when there was under-
standing about heterozygosity), which accounted for 16 
cases (55.2%), and unsatisfactory, which amounted to 13 
cases (44.8%). There was a positive correlation between 
illiteracy and poor understanding.26 In São Carlos, the line 
of care for individuals with hemoglobinopathies is orga-
nized from the BHU. There is no specialized service specif-
ically for this kind of health care. This might explain why, 
although the coverage of PNTN is higher in São Carlos that 
in Dourados, the frequency of tested family members and 
the level of understanding about the hereditary nature of 
the condition were lower. 
The Ministry of Health admits the possibility of testing 
parents and siblings, after the identification of a heterozy-
gous child,3 thus recognizing one of the additional benefits 
of neonatal screening, which is to allow the investigation 
and counseling of other family members.27 It is part of a 
health strategy, which believes that the identification of 
heterozygotes may have, secondarily, preventive effects.28 
The Brazilian proposal is to identify individuals at risk 
before they (re)start their reproductive plans, in order to 
inform them about the likelihood of generating sick chil-
dren in the future, thus expecting them to base their pre-
marital choices or reproductive decisions on this informa-
tion. We presume that the understanding of how inheri-
tance contributes to the disorder and the risk of recurrence 
would interfere with the establishment of reproductive 
associations and family planning.29
To some extent, the identification of heterozygotes in 
the neonatal screening programs for hemoglobinopathies 
brings tension to genetic disease prevention policies and 
promotion of fundamental rights (especially the right to 
reproductive autonomy) and it characterizes what Diniz 
and Guedes30 called the “new genetics”. The new genetics 
believes it controls the revival of eugenics authoritarianism 
by appealing to the ethical principles of human rights cul-
ture, such as individual autonomy, moral pluralism and tol-
erance. The use of genetic information based on the health 
rationale is a novelty that creates concerns to the humanist 
identity of this new discipline. Until recently, this duality 
of the new genetics was reasonably controlled by the 
restriction of genetic information to genetic counseling ses-
sions, i.e., for the privilege of clinical genetics, of which 
object is individual or family-related at maximum, at the 
expense of population genetics, which intervenes on a 
community. Currently, the increase in initiatives of commu-
nity genetics, such as the PNTN, has brought clinical genet-
ics closer to public health30, and for this reason, some 
authors consider that one of the great challenges of the 
new genetics is to ensure the moral credibility of the disci-
pline.31
Regarding genetic counseling, there is also the challenge 
of ensuring that the content of information provided to 
families are actually assimilated by them, thus guarantee-
ing the understanding of the condition. An important part 
of this function should be to explain the difference between 
having the disease and having the trait, the transmission of 
the alteration, where it comes from and the possibilities of 
affected offspring, both for parents and for the children, 
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explaining to them about the possible combinations of 
genes in an understandable and ethical way.30 In our study, 
we observed that little of this information was provided to 
those responsible for the child, and when the health edu-
cation process was performed, it was carried out as a con-
tingency, and not as routine. 
The Ministry of Health recommends that as the services 
of neonatal screening increase their population coverage 
and the spectrum of screened disorders, they must include 
a clinical geneticist performing genetic counseling of these 
families and coordinating what the Ministry called “Genetic 
Counseling in the Scope of the Population Screening 
Program”3 Due to the scarcity of medical geneticists,32 this 
recommendation is not followed in most neonatal screening 
services in the country.
The municipality of São Carlos has a high neonatal 
screening coverage, but subsequent stages of the program 
need improvement. In both scenarios investigated (mater-
nity hospital and BHU), health professionals need training 
to advise mothers and families. In addition, the Health 
Units that comprise the BHUs need to ensure an adequate 
record of users, allowing cases to be recalled for new tests 
faster. In situations where the screening results indicated 
alterations, families need to be better informed about 
genetic counseling and follow-up.
A possible limitation of this study is related to the mem-
ory bias, as many investigated aspects were related to past 
events in the years 2010 and 2011, and there may have 
been recall errors by the interviewed mothers. Furthermore, 
because this is a study of a series of cases, there is no con-
trol group for comparison.
Hemoglobinopathies represent a genetic disorder with 
high prevalence and their screening is the first step in pre-
vention. Neonatal screening coverage is increasing in num-
bers, year by year, and gaining importance as public policy; 
however, if the next steps of the PNTN do not increase at 
the same rate, the detection of initially abnormal tests 
loses meaning. 
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